VSAR News Alert Versartis Inc. (VSAR) 18.04 02/14/2015 20:36

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 9:36 PM

Versartis Inc. (VSAR) 18.04 $VSAR

Versartis Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Thu Feb 12, 4:07PM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced financial results for the fourth quarter and full year ended December 31, 2014.
VSAR: 18.04 (-0.55)

Versartis misses by $0.21
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 4:05PM CST

VSAR: 18.04 (-0.55)

Versartis to Present at the 2015 BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:05PM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced that Jeffrey L. Cleland, PhD, Chief Executive Officer, is scheduled to present at the 2015 BIO CEO & Investor Conference on Tuesday, February 10, 2015 at The Waldorf Astoria in New York City.
VSAR: 18.04 (-0.55)

InsiderInsights.com Daily Round Up 1/29/15: BGG, FPRX, OPK, WIW
InsiderInsights - at Seeking Alpha - Sat Jan 31, 11:09AM CST

STX: 61.83 (+0.67), CSWC: 46.54 (+1.20), FCS: 16.37 (-0.07), MLNK: 3.78 (+0.04), ADBE: 76.51 (+1.92), VSAR: 18.04 (-0.55), LCI: 57.78 (-0.91), WIW: 11.29 (unch), QRVO: 70.03 (+3.83), PSEM: 14.82 (-0.12), OPK: 13.80 (-0.28), CUDA: 35.68 (-1.14), BGG: 20.18 (+0.09), RWC: 5.82 (+0.06), PE: 17.28 (+0.80), MSFT: 43.87 (+0.78), BK: 39.20 (-0.21), FPRX: 24.63 (+0.63), INFN: 17.56 (-0.10)

InsiderInsights.com Daily Round Up 1/26/15: THRM, FXCM, OPK, TCBI
InsiderInsights - at Seeking Alpha - Wed Jan 28, 3:00AM CST

AZZ: 44.86 (+0.22), IGTE: 39.53 (+0.62), BALT: 1.74 (+0.09), EGBN: 36.43 (-0.31), FXCM: 2.21 (-0.01), TCBI: 48.51 (+0.81), THRM: 41.21 (+0.38), VEEV: 30.12 (+0.17), VSAR: 18.04 (-0.55), PN: 13.35 (-0.14), LNKD: 269.00 (+1.83), OPK: 13.80 (-0.28), NERV: 4.68 (+0.09), CAS: 6.14 (-0.01), SGNT: 27.75 (-0.41), ARIA: 7.35 (+0.45), TWTR: 48.50 (+0.55), BKE: 49.59 (-0.16)

Versartis prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 6:32AM CST

VSAR: 18.04 (-0.55)

Versartis Announces Pricing of Follow-On Offering
GlobeNewswire - Wed Jan 21, 7:44PM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced the pricing of an underwritten public offering of 4,347,826 shares of its common stock at a price to the public of $17.25 per share. In addition, Versartis has granted the underwriters a 30-day option to purchase up to 652,173 additional shares of common stock. The offering is expected to close on January 27, 2015, subject to customary closing conditions.
VSAR: 18.04 (-0.55)

Nasdaq stocks posting largest percentage decreases
AP - Wed Jan 21, 5:01PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
VSAR: 18.04 (-0.55), IMDZ: 25.34 (+1.20), ADXS: 7.18 (+0.06), ALDX: 11.01 (-0.25), ACTG: 13.13 (+0.04), BONT: 5.79 (+0.04), IMKTA: 42.26 (-0.18), AAVL: 36.29 (+0.01), OUTR: 68.39 (+2.22)

Versartis Announces Proposed Offering of Common Stock
GlobeNewswire - Tue Jan 20, 5:10AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $75,000,000. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. All of the shares in the offering will be sold by Versartis.
VSAR: 18.04 (-0.55)

Versartis Initiates Global Phase 3 Study of VRS-317 in Children With Growth Hormone Deficiency
GlobeNewswire - Thu Jan 08, 7:50AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced the initiation of its Phase 3 study of VRS-317 for semi-monthly dosing in children with growth hormone deficiency (GHD). This registration trial follows positive data from the Company's completed Phase 1b/2a VERTICAL study and the ongoing long-term Extension Study.
VSAR: 18.04 (-0.55)

Versartis Announces Positive 12 Month Data for VRS-317 from Ongoing Extension Study
PR Newswire - Mon Jan 05, 7:00AM CST
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced positive data from its Extension Study of VRS-317 for naive to treatment, pre-pubertal children with growth hormone deficiency (GHD). The Extension Study is a long-term safety study initiated in March 2014 as patients completed the Versartis' Phase 1b/2a clinical trial of VRS-317 in children with GHD.
VSAR: 18.04 (-0.55)

Versartis to Hold Conference Call to Discuss VRS-317 Clinical Update From Ongoing Extension Study
GlobeNewswire - Mon Dec 29, 7:36AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced it will hold a conference call and webcast on Monday, January 5, 2015 at 8:30 a.m. ET (5:30 a.m. PT).
VSAR: 18.04 (-0.55)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)

InsiderInsights.com Daily Round Up 11/20/14: NES, OPK, OKS, PAH
InsiderInsights - at Seeking Alpha - Mon Nov 24, 2:04PM CST

NES: 3.52 (+0.13), RAX: 50.01 (+0.24), JAH: 51.18 (+0.18), LNG: 74.48 (+0.90), MRD: 18.66 (+0.23), PAH: 22.68 (+0.14), AON: 100.56 (-0.18), SGM: 10.68 (+0.08), CLI: 19.81 (-0.02), CNCE: 12.76 (-0.46), VSAR: 18.04 (-0.55), OPK: 13.80 (-0.28), HZNP: 16.84 (-0.41), CATY: 26.14 (+0.42), IMH: 9.97 (+0.10), OKS: 45.47 (+0.07), GRPN: 7.97 (+0.51), SFXE: 3.49 (+0.01), SCHW: 29.13 (-0.83)

Versartis to Present at the 26th Annual Piper Jaffray Health Care Conference
GlobeNewswire - Mon Nov 24, 7:30AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced that Jeffrey L. Cleland, PhD, Chief Executive Officer, is scheduled to present at the 26 Annual Piper Jaffray Health Care Conference on Tuesday, December 2, 2014 at the New York Palace Hotel in New York City.
VSAR: 18.04 (-0.55)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...